This (Sloan-Kettering Institute for Cancer Research) consideration focuses on in vivo assessment of enhancing tumor replication to radiation (XRT) and adriamycin.

This (Sloan-Kettering Institute for Cancer Research) consideration focuses on in vivo assessment of enhancing tumor replication to radiation (XRT) and adriamycin, according to pretreatment with 6-aminonicotinamide (6AN) in the hormone sensitive MCF-7 Tumors are innoculated forward the flank of nude mice, and are studied. The dose of 6AN for all experiments is 16 mg/kg which is given 10 hours prior to adriamycin or XRT (5 Gy) The research goal is to investigate the efficacy of 6AN to enhance the weight of radiation and chemotherapy agents that are used in treating breast cancer. The contemplation is based on previous work that indicates that 6AN enhances the meaning of radiation in vitro (RIF-1 tumor cells) and in vivo (breast cancer tumor). The criticism of this previous research is that the studies were not done in human tumors. Therefore, this research undertakes human studies to determine if it is possible to copy the previous results in human breast cancer cell/tumors. The previous in vitro studies did indicate that 6AN does enhance the weight of radiation and adriamycin, however not paclitaxel.

(Order this LIFE SCIENCES & BIOTECHNOLOGY UPDATE reviewed report from InfoTeam Inc., PO chest 15640, Plantation, FL 33318-5640; Phone (954) 473-9560 Fax (954) 473-0544: Report No. L20010819; 2000 20 pp Price: $8900 prepaid.)

...

Home